Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Clinical trial NCT03980938 · TERMINATED
Trial details
- NCT number
- NCT03980938
- Sponsor
- EIP Pharma Inc
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-08
- Primary completion
- 2020-10-15
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.